Role of four new blood coagulation tests in cancer stem cell-mediated tumor-related venous thromboembolism.
- 1The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, Yichang, 443000, Hubei, China.
Abstract
Patients with cancer often have a marked hypercoagulable state, which significantly raises the risk of thrombosis. Recent studies have shown that cancer stem cells (CSCs) play a crucial role in creating this prothrombotic environment by influencing the coagulation cascade and triggering thromboinflammation. This review comprehensively examines the role of four novel blood coagulation tests - thrombomodulin (TM), thrombin-antithrombin complex (TAT), plasmin-α2-antiplasmin complex (PIC), and tissue-type plasminogen activator-inhibitor 1 complex (t-PAIC) - in the context of cancer stem cell-mediated tumor-related venous thromboembolism (VTE). These markers offer distinct advantages over traditional coagulation assays for dynamic monitoring of coagulation and fibrinolysis in cancer-associated VTE, providing a more nuanced assessment of patient status. We elucidate the predictive, diagnostic, and risk-assessment value of this "four-item test," exploring its potential to identify patients at high risk of VTE and to monitor treatment efficacy. Furthermore, we delve into the underlying pathophysiological links connecting CSC activity, cancer-associated thrombosis (CAT), thromboinflammation, and the formation of neutrophil extracellular traps (NETs), suggesting that these biomarkers may offer valuable insights into the mechanisms driving thrombosis in cancer.
Related
- CO012 | LONG-TERM RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN ADULT PATIENTS WITH ACTIVE CANCER AND FIRST CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS AFTER DISCONTINUATION OF ANTICOAGULANT TREATMENTS AND LINE REMOVAL: A RETROSPECTIVE MULTI-CENTER COHORT STUDY – CANCER-CRT STUDY
- Recurrent venous thromboembolism despite natural cycle frozen embryo transfer in a woman with a history of pregnancy-related venous thromboembolism: A case report.
- Low Body Weight as a Marker of Vulnerability in Cancer-Associated Venous Thromboembolism
- The Hidden Burden of Cancer-Associated Venous Thromboembolism ― An Emerging Challenge in Cardio-Oncology ―
- Knowledge, attitudes, and practices regarding venous thromboembolism prevention in patients with lung cancer
BibTeX
@article{zhou2026role,
title = {{Role of four new blood coagulation tests in cancer stem cell-mediated tumor-related venous thromboembolism.}},
author = {Nina Zhou and Sai Chen},
journal = {BioImpacts : BI},
year = {2026},
month = jul,
doi = {10.34172/bi.33600},
url = {https://europepmc.org/article/MED/42898415},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Role of four new blood coagulation tests in cancer stem cell-mediated tumor-related venous thromboembolism.
AU - Nina Zhou
AU - Sai Chen
PY - 2026
DA - 2026/07/22
JO - BioImpacts : BI
DO - 10.34172/bi.33600
UR - https://europepmc.org/article/MED/42898415
AB - Patients with cancer often have a marked hypercoagulable state, which significantly raises the risk of thrombosis. Recent studies have shown that cancer stem cells (CSCs) play a crucial role in creating this prothrombotic environment by influencing the coagulation cascade and triggering thromboinflammation. This review comprehensively examines the role of four novel blood coagulation tests - thrombomodulin (TM), thrombin-antithrombin complex (TAT), plasmin-α2-antiplasmin complex (PIC), and tissue-type plasminogen activator-inhibitor 1 complex (t-PAIC) - in the context of cancer stem cell-mediated tumor-related venous thromboembolism (VTE). These markers offer distinct advantages over traditional coagulation assays for dynamic monitoring of coagulation and fibrinolysis in cancer-associated VTE, providing a more nuanced assessment of patient status. We elucidate the predictive, diagnostic, and risk-assessment value of this "four-item test," exploring its potential to identify patients at high risk of VTE and to monitor treatment efficacy. Furthermore, we delve into the underlying pathophysiological links connecting CSC activity, cancer-associated thrombosis (CAT), thromboinflammation, and the formation of neutrophil extracellular traps (NETs), suggesting that these biomarkers may offer valuable insights into the mechanisms driving thrombosis in cancer.
SN - 2228-5652
SN - 2228-5660
ER -